Please note that following on from information provided to NICE by the company in June 2014, the appraisal of Faldaprevir for treating genotype 1 chronic hepatitis C [ID670] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 670 |
| Referral date | 01 February 2014 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in June 2014, the appraisal of Faldaprevir for treating genotype 1 chronic hepatitis C [ID670] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 July 2014 | The manufacturer of faldaprevir, Boehringer Ingelheim, has informed us that it has decided not to proceed with the development of faldaprevir for treating hepatitis C. Boehringer Ingelheim has re-evaluated its strategy in hepatitis C, and considers that there are now several new treatment options available for patients and that there is no longer an unmet medical need that would be filled with its faldaprevir interferon-based regimen |
For further information on our processes and methods, please see our CHTE processes and methods manual